CoChat

Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study

Devine, Angela, Battle, Katherine E., Meagher, Niamh, Howes, Rosalind E., Dini, Saber, Gething, Peter W., Simpson, Julie A., Price, Ric N., Lubell, Yoel · 2021 · PLOS Medicine
Cited by 33

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: In 2017, an estimated 14 million cases of Plasmodium vivax malaria were reported from Asia, Central and South America, and the Horn of Africa. The clinical burden of vivax malaria is largely driven by its ability to form dormant liver stages (hypnozoites) that can reactivate to cause recurrent episodes of malaria. Elimination of both the blood and liver stages of the parasites (“radical cure”) is required to achieve a sustained clinical response and prevent ongoing transmission of the parasite. Novel treatment options and point-of-care diagnostics are now available to ensure that radical cure can be administered safely and effectively. We quantified the global economic cost of vivax malaria and estimated the potential cost benefit of a policy of radical cure after testing patients for glucose-6-phosphate dehydrogenase (G6PD) deficiency. Methods and findings: Estimates of the healthcare provider and household costs due to vivax malaria were collated and combined with national case estimates for 44 endemic countries in 2017. These provider and household costs were compared with those that would be incurred under 2 scenarios for radical cure following G6PD screening: (1) complete adherence following daily supervised primaquine therapy and (2) unsupervised treatment with an assumed 40% effectiveness. A probabilistic sensitivity analysis generated credible intervals (CrIs) for the estimates. Globally, the annual cost of vivax malaria was US$359 million (95% CrI: US$222 to 563 million), attributable to 14.2 million cases of vivax malaria in 2017. From a societal perspective, adopting a policy of G6PD deficiency screening and supervision of primaquine to all eligible patients would prevent 6.1 million cases and reduce the global cost of vivax malaria to US$266 million (95% CrI: US$161 to 415 million), although healthcare provider costs would increase by US$39 million. If perfect adherence could be achieved with a single visit, then the global cost would fall further to US$225 million, equivalent to $135 million in cost savings from the baseline global costs. A policy of unsupervised primaquine reduced the cost to US$342 million (95% CrI: US$209 to 532 million) while preventing 2.1 million cases. Limitations of the study include partial availability of country-level cost data and parameter uncertainty for the proportion of patients prescribed primaquine, patient adherence to a full course of primaquine, and effectiveness of primaquine when unsupervised. Conclusions: Our modelling study highlights a substantial global economic burden of vivax malaria that could be reduced through investment in safe and effective radical cure achieved by routine screening for G6PD deficiency and supervision of treatment. Novel, low-cost interventions for improving adherence to primaquine to ensure effective radical cure and widespread access to screening for G6PD deficiency will be critical to achieving the timely global elimination of P . vivax .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1003614

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 41

  1. RN Price, 2020, Plasmodium vivax in the Era of the Shrinking P. falciparum Map, Trends Parasitol, 36, 560, 10.1016/j.pt.2020.03.009 · DOI · Paper page
  2. S Dini, 2020, The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study., BMC Med., 18, 28, 10.1186/s12916-020-1497-0 · DOI · Paper page
  3. NM Douglas, 2013, Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax, J Infect Dis, 208, 801, 10.1093/infdis/jit261 · DOI
  4. NM Douglas, 2014, Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia, BMC Med, 12, 217, 10.1186/s12916-014-0217-z · DOI
  5. JR Poespoprodjo, 2009, Vivax Malaria: A Major Cause of Morbidity in Early Infancy, Clin Infect Dis, 48, 1704, 10.1086/599041 · DOI · Paper page
  6. World Health Organisation, 2015, Guidelines for the Treatment of Malaria
  7. NM Douglas, 2017, Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study, PLoS Med, 14, e1002379, 10.1371/journal.pmed.1002379 · DOI · Paper page
  8. T Leslie, 2004, Compliance with 14-day primaquine therapy for radical cure of vivax malaria—a randomized placebo-controlled trial comparing unsupervised with supervised treatment, Trans R Soc Trop Med Hyg, 98, 168, 10.1016/S0035-9203(03)00041-5 · DOI · Paper page
  9. CS Chu, 2018, Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria, Clin Infect Dis
  10. WRJ Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
  11. MVG Lacerda, 2019, Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
  12. EA Ashley, 2014, Primaquine: the risks and the benefits, Malar J, 13, 418, 10.1186/1475-2875-13-418 · DOI · Paper page
  13. RE Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map, PLoS Med., 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
  14. K Thriemer, 2017, Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group, Malar J., 16, 141, 10.1186/s12936-017-1784-1 · DOI · Paper page
  15. A Devine, 2019, Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data, Bull World Health Organ, 97, 828, 10.2471/BLT.18.226688 · DOI
  16. B Ley, 2019, Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis, PLoS Med, 16, e1002992, 10.1371/journal.pmed.1002992 · DOI · Paper page
  17. PW Gething, 2012, A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010, PLoS Negl Trop Dis, 6, e1814, 10.1371/journal.pntd.0001814 · DOI · Paper page
  18. JK Baird, 2018, Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms, Malar J, 17, 42, 10.1186/s12936-018-2190-z · DOI
  19. Management Sciences for Health. International Medical Products Price Guide, 2015 Edition. Arlington, VA: Management Sciences for Health; 2017 [cited 2017 October 26]. Available from: http://mshpriceguide.org/en/home/.
  20. BA Rahimi, 2014, Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900., Malar J, 13, 481, 10.1186/1475-2875-13-481 · DOI · Paper page
  21. C Botto-Menezes, 2016, Costs Associated with Malaria in Pregnancy in the Brazilian Amazon, a Low Endemic Area Where Plasmodium vivax Predominates, PLoS Negl Trop Dis, 10, e0004494, 10.1371/journal.pntd.0004494 · DOI
  22. E Kenangalem, 2019, Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study, PLoS Med., 16, e1002815, 10.1371/journal.pmed.1002815 · DOI
  23. HM Peixoto, 2016, Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon, Malar J, 15, 82, 10.1186/s12936-016-1140-x · doi:10.1186/s12936-016-1140-x
  24. MR de Oliveira, 2012, Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil, Malar J, 11, 390, 10.1186/1475-2875-11-390 · DOI
  25. R Milligan, 2020, Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax, Cochrane Database Syst Rev, 8, Cd012656
  26. RJ Commons, 2020, Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis, Am J Trop Med Hyg
  27. Q Bassat, 2016, Key Knowledge Gaps for Plasmodium vivax Control and Elimination, Am J Trop Med Hyg
  28. JA Mulligan, 2006, The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania, Trop Med Int Health, 11, 452, 10.1111/j.1365-3156.2006.01590.x · DOI
  29. JD Njau, 2008, The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania, Malar J, 7, 4, 10.1186/1475-2875-7-4 · doi:10.1186/1475-2875-7-4
  30. AR Taylor, Resolving the cause of recurrent Plasmodium vivax malaria probabilistically, Nat Commun, 10, 5595, 10.1038/s41467-019-13412-x · DOI · Paper page
  31. AI Adekunle, 2015, Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo, PLoS Negl Trop Dis, 9, e0003595, 10.1371/journal.pntd.0003595 · DOI · Paper page
  32. KP Grietens, 2010, Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon, Am J Trop Med Hyg, 82, 1017, 10.4269/ajtmh.2010.09-0521 · DOI
  33. K Thriemer, 2018, Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group, Malar J, 17, 241, 10.1186/s12936-018-2380-8 · DOI · Paper page
  34. MT White, 2018, Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax, Nat Commun, 9, 3300, 10.1038/s41467-018-05860-8 · DOI
  35. NM Douglas, 2012, Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria, Adv Parasitol, 80, 271, 10.1016/B978-0-12-397900-1.00005-0 · DOI
  36. S Vitor-Silva, 2009, Malaria is associated with poor school performance in an endemic area of the Brazilian Amazon., Malar J., 8, 230, 10.1186/1475-2875-8-230 · DOI
  37. AM Lucas, 2010, Malaria Eradication and Educational Attainment: Evidence from Paraguay and Sri Lanka, Am Econ J Appl Econ, 2, 46, 10.1257/app.2.2.46 · DOI · Paper page
  38. AM Lucas, 2013, The Impact of Malaria Eradication on Fertility, Econ Dev Cult Change, 61, 607, 10.1086/669261 · DOI
  39. H. Bleakley, 2010, Malaria Eradication in the Americas: A Retrospective Analysis of Childhood Exposure, Am Econ J Appl Econ, 2, 1, 10.1257/app.2.2.1 · DOI · Paper page
  40. KE Battle, 2015, Defining the relationship between Plasmodium vivax parasite rate and clinical disease, Malar J, 14, 191, 10.1186/s12936-015-0706-3 · DOI
  41. S Pal, 2019, Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient, Am J Trop Med Hyg, 100, 213, 10.4269/ajtmh.18-0612 · DOI · Paper page

Cited by

See all 33

Metadata

Authors
Devine, A., Battle, K. E., Meagher, N., Howes, R. E., Dini, S., Gething, P. W., Simpson, J. A., Price, R. N., & Lubell, Y.
Venue
PLOS Medicine
Published
2021-06-01
Volume
18
Issue
6
Pages
e1003614
ISSN
1549-1676
Cited by
33
References
6
Language
en
Funders
  • Bill and Melinda Gates Foundation (INV-007122, INV-009390)
  • National Health and Medical Research Council (1134989, 1104975)
  • Wellcome Trust (200909)
  • Channel 7 Telethon Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study. https://app.cochat.ai/papers/10.1371/journal.pmed.1003614
The paper
Devine, A., Battle, K. E., Meagher, N., Howes, R. E., Dini, S., Gething, P. W., Simpson, J. A., Price, R. N., & Lubell, Y. (2021). Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1003614

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.